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Abstract: The role played by different humoral factors, including antiphospholipid antibodies, in the pathogenesis of 
Tourette syndrome (TS) is still presently unclear. We present a patient with chronic and severe TS who, at the age of 16 
years, presented an ischemic stroke in the left posterior cerebral artery and/or postero-inferior temporal branch of the left 
medial cerebral artery. A complete study was negative with the exception of a positive lupus anticoagulant. The stroke 
was related with the primary antiphospholipid syndrome (APS). The stroke manifested visual abnormalities and thereafter 
by secondary generalized complex partial seizures. The epileptic syndrome was initially difficult to control but responded 
dramatically to levetiracetam. With this therapy, the manifestations of TS, especially the tics, improved. We conclude that 
some TS cases may present APS. In addition, levetiracetam may be useful in the management of TS. Further investiga-
tions should pursue both these facts. 
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INTRODUCTION 
  The pathogenesis of the Tourette syndrome (TS), the 
main component of the primary tic-syndrome [1], is pres-
ently unclear. Both genetic and non-genetic factors are im-
portant considerations [2-8]. The antiphospholipid antibodies 
(aPLAs) are a group of heterogeneous antibodies which bind 
with negatively charged phospholipids. When present in as-
sociation with vascular thrombosis or recurrent fetal loss, the 
diagnostic criteria of the antiphospholipid syndrome (APS) 
are fulfilled [6]. The neurological complications of APS are 
varied and include movement disorders and chorea. How-
ever, the mechanism underlying non-thrombotic movement 
disorders in APS remains presently unknown. A direct im-
mune interaction of aPLAs with diverse brain structures has 
been hypothesized.
 Presently, there is conflicting evidence of 
an association of aPLA with TS [7-8].  
  Herein, we present a young patient with severe TS who 
presented an ischemic stroke in association with APS and 
secondarily presented epileptic syndrome. We reappraise the 
hypothesis that aPLAs may play a role in TS. In addition, we 
highlight the fact that levetiracetam therapy had a significant 
beneficial effect in the control of the tics and the epileptic 
syndrome. 
CASE REPORT 
  The patient is presently a 25 year-old male with a family 
history for a transient tic-disorder present in the infancies of 
both his father and paternal grandfather. He was born after  
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an uneventful pregnancy and birth. From the age of 8 years 
he presented a progressive and severe complex motor and 
vocal tic disorder including echolalia, palilalia and coprolalia 
in association with obsessive-compulsive behavior. He was 
diagnosed of TS. The severity of the syndrome required mul-
tiple evaluations over the years in various neurological cen-
ters and by the psychiatry department. He was treated with 
multiple combination therapies with neuroleptics, anticho-
linergics and tricyclics but the clinical response was basi-
cally poor. The tic disorder had a severe and negative impact 
in his family, social relations and on his academic results. In 
this period, an extensive and complete study including neu-
roimaging studies with CT and MRI were normal. At the age 
of 16 years, he presented sudden-onset blurring in his left 
hemifield followed by a tonic-clonic seizure of minutes´s 
duration. No motor, sensory or language abnormalities were 
present. The brain CT and MRI showed the presence of a 
right parietal-occipital ischemic stroke (Fig. 1a,b,c,d). An 
angio-MRI of the brain and neck vessels was normal. An 
electrocardiogram and trans- esophageal echocardiogram 
were normal. Thyroid function and coagulation studies were 
normal. In the serum, titers of nuclear antibodies (ANAs), 
performed by indirect inmunofluoresce using rat liver and 
mouse kidney were positive with 1/640 titer and the anti-
DNA, antihistone, anti-SSA, anti-SSB and anti-RNP anti-
bodies were negative; C3 and C4 serum levels were normal. 
The syphilis serology and anticardiolipin antibodies were 
negative. The lupus anticoagulant was positive (dRVVT, 
Instrumentations Laboratory) on two tests performed in an 
interval of 12 months. 
  The left-sided visual abnormalities improved over a few 
weeks. However, the seizure disorder persisted. The seizures 
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an oppressive epigastric sensation, tachycardia, diaphoresis 
and visual alterations. These visual phenomena were rich and 
varied in type: metamorphopsia, positive phenomena of 
complex nature in the left hemifield, and a vague sensation 
described as “far vision”. Some of these episodes were fol-
lowed by a head turning to the left and impaired conscious-
ness and confusion of variable but, generally brief, duration. 
He was diagnosed of secondary generalized complex partial 
(autonomic, visual and versive) epilepsy and the patient was 
managed with antiepileptic drugs (AED) in various combina-
tions (valproate, carbamacepine, phenobarbital and pheny-
toin). These agents were mainly effective on the generalized 
convulsive fits, but the other phenomena persisted, were fre-
quent (2-4 per week) and motivated many consultations in 
the emergency room.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). a. Brain CT. Hypodense right occipital lobe lesion (arrow) 
with dilatation of the ventricular horn and widened cortical sulci 
(atrophy).  
b. Brain MRI (FLAIR). Axial section. Hyperintense white matter 
signal in the occipital lobe (arrow), ventricular dilatation and wid-
ened sulci.  
c-d. Brain MRI (T2 weighted). Coronal section. Hypointense signal 
in the right occipital lobe with a peripheral hyperintensity (arrow) 
suggestive of a chronic ischemic infarct. 
 
  At the age of 21 years levetiracetam 1000mg bid was 
initiated as add-on therapy to phenytoin 300 mg/day and the 
seizure disorder came under complete and total control. Si-
multaneously, with the initiation of levetiracetam, the tic-
disorder (both the motor and vocal tics) improved in parallel 
with the control of the seizure disorder. The patient main-
tains treatment with platelet inhibitors and levetiracetam; the 
dose of phenytoin is being progressively lowered (presently 
at 100 mg/day). He is seizure-free since the initiation of 
levetiracetam therapy. 
  The patient still presents occasional vocal and motor tics 
but is able to lead a satisfactory personal and social life. In 
addition, he has earned an employment as a public servant. 
DISCUSSION 
  This patient with severe TS presented an ischemic stroke 
in the posterior cerebral artery and/or postero-inferior tempo-
ral branch of the right medial cerebral artery. A stroke work-
up was negative with the exception of a positive lupus anti-
coagulant repeated on various occasions. Systemic diseases 
were excluded and the patient satisfied the diagnostic criteria 
for primary APS [6]. The stroke manifested visual abnor-
malities and secondary generalized complex partial seizures. 
Upon reaching a good control of the seizures the manifesta-
tions of the TS improved. 
  The pathogenesis and pathophysiology of TS are still 
presently unknown. Abnormalities in both the dopaminergic 
and, to a lesser extent, serotoninergic neurotransmission 
within the basal ganglia and the cortico-ganglionic-thalamo-
cortical circuitry have been suggested [2].  
  Both genetic and non-genetic factors may play a role in 
the pathogenesis of TS. The presence of certain cytogenetic 
abnormalities, including chromosomal translocations and 
inversions, and epigenetic risk factors suggest that certain 
genetic or chromosomal irregularities may be common to 
some cases of TS [2]. There is also evidence for an immu-
nological basis in TS. Anti-basal ganglia antibodies appear 
to play a role in certain TS-spectrum disorders including the 
pediatric autoimmune neuropsychiatric disorders associated 
with streptococcal infection (PANDAS). These antibodies 
have been found in 65% of patients with atypical movement 
disorders [3]. Anti-basal ganglia antibodies are often found 
in children with Sydenham´s chorea. In this disease, antibod-
ies seem to attack the basal ganglia by a mechanism of mo-
lecular mimicry triggered by a previous streptococcal infec-
tion [8]. In TS there are higher concentrations of anti-
putaminal antibodies compared to normal controls [5] and 
immunomodulatory treatment is effective in some patients. 
There are therapies that may act on a putative immune-
mediated attack directed against the nigrostriatal or prefron-
tal dopaminergic pathways [3,9]. 
  Some studies have approached the possible association 
between aPLAs and TS. Antiphospholipid antibodies have 
been identified in children with TS and have led to the 
speculation that these antibodies might play a pathophysi-
ological and possibly pathogenic role in this condition [7]. If 
confirmed, the presence of aPLAs has diagnostic and thera-
peutic implications in TS. However, aPLAs in TS may rep-
resent an epiphenomenon rather than a pathophysiological 
mechanism [8]. Unfortunately, the number studies on this 
aspect are scarce and have not included patients with APS.  
  To our knowledge, this is the first report of a TS patient 
presenting a stroke in association with APS. Acknowledging 
a possible chance association, in some TS cases immune 
phenomena may be involved in the movement disorders. The 
presence of a particular genetic load or predisposition may 
increase susceptibility in developing specific antibodies and 
thrombotic phenomena.  
  Also of interest in this case is the favorable response of 
both the epileptic syndrome and the tic-disorder to 
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levetiracetam. It is possible that the seizure disorder may 
have aggravated the frequency and severity of the tics but we 
do not exclude a direct effect of levetiracetam on the favor-
able outcome of the tic-disorder [10]. 
  In conclusion, this report indicates that aPLAs may be 
present in some patients with TS. We believe that the mecha-
nisms that trigger the generation of these antibodies leading 
to vascular events and possibly movement disorders should 
be further investigated. 
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